The agentic platform for private equity due diligence.

The Program of All-Inclusive Care for the Elderly, or PACE, is a federally regulated managed care program that integrates medical, social, and long-term support services for nursing-home-eligible adults who choose to remain in their communities rather than enter residential care facilities. Meridian PACE Holdings operates 12 PACE centers across California and Arizona, serving approximately 4,200 participants, positioning the company as the fourth-largest independent PACE operator in the United States with $312M in trailing twelve-month revenue and 14.2% EBITDA margins.

The US PACE market is estimated at $3.8B–$4.2B in 2025, growing at 8–11% CAGR through 2029. Growth is driven by three structural factors: Medicare Advantage penetration reaching 52% nationally (MA enrollment triggers greater PACE awareness among dual-eligible adults), CMS risk adjustment methodology changes in 2024 that expanded the PACE-eligible population by approximately 2.3 million lives, and an aging demographic base with the 85-and-older cohort projected to double between 2025 and 2040. The PACE model remains structurally undersupplied relative to its eligible population: fewer than 75,000 adults are enrolled nationally against an estimated 12 million dual-eligible Americans who meet PACE clinical criteria.

Six findings require immediate attention from the deal team. First, Meridian’s top 10 payers represent 34% of revenue, with UnitedHealth contributing 8.2%; concentration has declined from 41% in 2022 but remains above the peer median of 28%. Second, secondary research on California PACE licensure indicates timelines averaging 22 months, materially longer than the 9-month estimate in the CIM, which directly impacts the Year 3 center count in management’s base case. Third, financial model analysis indicates two Arizona centers operating below 70% census, inconsistent with the CIM’s uniform 85% claim and contributing negative contribution margin after allocated overhead. Fourth, the EHR migration from Allscripts to Epic, budgeted at $4.2M over 14 months, carries elevated execution risk: secondary research indicates PACE-specific Epic implementations average 18–22 months given the complexity of interdisciplinary care team workflows. Fifth, Meridian’s California Medicaid PMPM rates are subject to state budget renewal every two years; a one-year rate freeze in the 2025–2026 California budget cycle would reduce Year 2 EBITDA by approximately $4.8M at current enrollment levels. Sixth, the CIM does not disclose retention terms for the three senior leaders who built Meridian’s California operations, creating a management continuity risk under PE-backed acceleration from 12 to 18 centers.

The combined revenue and margin impact of the licensure timeline discrepancy and the two underperforming Arizona centers could reduce Year 3 EBITDA by $12M–$18M relative to management’s base case, narrowing the Year 3 margin from 19% to approximately 16–17% at the midpoint scenario. These scenarios are quantified in full in the Investigation Agenda (Section 8).

The Investigation Agenda identifies 7 priority investigation threads and 2 strategic hypotheses, including a licensure sensitivity model with three scenarios and a CMS reimbursement stress test quantifying EBITDA impact across four rate trajectories. Threads are prioritized by their potential impact on the investment recommendation.

PACE was established as a permanent Medicare and Medicaid benefit under the Balanced Budget Act of 1997, building on the On Lok model that originated in San Francisco’s Chinatown in 1983. The program serves adults aged 55 and older who are certified as nursing-home eligible by their state Medicaid agency but who prefer to remain in the community. PACE is the only program in the US healthcare system where a single organization assumes complete financial and clinical responsibility for every service a participant needs, from primary care and dentistry to hospitalization, pharmacy, and home care. This all-inclusive mandate distinguishes PACE structurally from every other managed care model.

Participants are dually enrolled in Medicare and Medicaid simultaneously. CMS pays a monthly capitation rate per enrolled participant (the Medicare PMPM), derived from county-level Medicare Advantage benchmarks and adjusted for each participant’s clinical acuity using the CMS-HCC risk adjustment model. The state Medicaid agency pays a separate Medicaid PMPM rate negotiated through a three-way contract between CMS, the state, and the PACE organization. For Meridian’s California centers, the combined Medicare and Medicaid PMPM averages approximately $4,400 per participant per month; Arizona averages approximately $3,800, reflecting California’s higher Medicaid rates. Critically, these payments are received regardless of how much or how little care a participant uses in any given month, creating strong economic incentives to invest in preventive care programs that reduce hospitalizations, the single largest cost driver in the PACE cost structure.

PACE vs. Alternatives: Structural Comparison

Meridian operates a hub-and-spoke model with each of its 12 centers functioning as a self-contained care delivery unit. Each center is staffed by an interdisciplinary team (IDT) including physicians, nurse practitioners, registered nurses, physical and occupational therapists, social workers, registered dietitians, and home care coordinators. Participants receive day health services 2 to 5 days per week at the PACE day center; home visits and transportation are coordinated by the IDT. The average center serves 350 participants at an 85% census rate. Financial model analysis indicates two Arizona centers currently operating below 70% census, a fact not disclosed in the CIM.

Revenue is composed of three streams: CMS capitated payments (72%), Medicaid supplemental payments (21%), and ancillary services including pharmacy and durable medical equipment (7%). The capitated structure provides strong revenue visibility, with 93% of revenue recurring on monthly capitation schedules. A PACE center reaches EBITDA breakeven at approximately 240 enrolled participants, reflecting the fixed staffing model of the IDT. Below breakeven, each additional enrolled participant adds approximately $2,800 to $3,200 per month in net contribution after variable costs. Mature centers (3 years of operation or more) generate contribution margins of 22–26%; centers in their first 18 months generate 8–12% as they ramp toward the breakeven threshold.

Management’s growth strategy centers on three levers: new center openings (2–3 per year), census growth within existing centers toward the 95% ceiling, and geographic expansion into Nevada and New Mexico, where PACE licensure frameworks were established following the 2015 PACE Innovation Act. The target of 18 centers by Year 3 implies 6 new openings in 36 months. Each new center requires a state-specific PACE program agreement with CMS, a Medicaid three-way contract negotiation, and facility development; the pre-application to first-revenue timeline averages 20–28 months across Meridian’s target states. Funding 6 new centers requires approximately $19.2M in buildout capital plus $19M–$24M in pre-breakeven operating losses, totaling $38M–$43M in capital requirements that organic cash flow at current margins cannot support without diluting existing operations.

The US PACE market is fragmented: 175 programs are operated by non-profit health systems, for-profit independents, and PE-backed platforms. The top 5 for-profit operators account for approximately 38% of market revenue. Meridian holds first-mover positions in 3 of its 8 California markets, a density advantage that is difficult for later entrants to replicate given the 20–28 month regulatory timeline per center.

Key PACE Operators

InnovAge Healthcare, taken private by Welsh Carson Anderson & Stowe in Q3 2024 at $2.1B enterprise value (14.5x trailing EBITDA), is the dominant national platform. InnovAge’s California presence is limited to 3 centers in Northern California, with limited direct overlap with Meridian’s Southern California and Central Valley footprint. WelbeHealth, backed by General Atlantic, operates 14 centers concentrated in Los Angeles, the Central Valley, and coastal California, directly overlapping with 4 of Meridian’s 8 California locations. WelbeHealth’s recent $420M equity raise signals continued aggressive California expansion, representing the most immediate competitive threat to Meridian’s home market.

PACE operators compete not only against other PACE programs but against the full continuum of post-acute and long-term care settings for dual-eligible adult enrollment. For a dual-eligible adult who becomes nursing-home eligible, the primary alternatives are a skilled nursing facility (averaging $110,000 per year in California), home health agency services under Medicare Part A (episodic, limited to post-acute recovery), and assisted living (primarily private pay). PACE’s competitive advantage in this comparison is its all-inclusive, capitated model at a total cost of care significantly below SNF placement; CMS has estimated that PACE participants would cost approximately 17% more if served in SNF settings. However, PACE requires participants to use the program’s preferred physicians and day center, a dependency that limits enrollment in lower-density and rural areas where transportation is a barrier.

The competitive risk in Arizona is concentrated in the Phoenix metropolitan area. InnovAge has filed applications with the Arizona Department of Health Services for 2 new PACE centers in Phoenix, which would bring total Phoenix-area PACE capacity to approximately 1,400 participants versus current aggregate active enrollment and waitlist demand of approximately 900 dual-eligible adults. This capacity overhang would directly pressure Meridian’s two Phoenix-area centers' census growth trajectories, as InnovAge’s national marketing infrastructure and payer relationships confer structural advantages in enrollment acquisition.

Meridian’s clinical staffing model has functioned as a competitive differentiator. The company retains medical directors at 88%, compared to a secondary research average of approximately 72% for the broader PACE industry. However, this retention advantage is partially offset by above-market physician compensation running 12–15% above market median, which accounts for approximately 1.4–1.8 percentage points of the gap between Meridian’s EBITDA margin and the peer group’s upper quartile.

An emerging structural threat comes from Medicaid managed care organizations. Several California MCOs are developing integrated programs for their dual-eligible members that replicate PACE-like care coordination within existing MA plan structures. These programs do not require the CMS PACE program agreement and are not subject to the same licensure barriers; if they achieve comparable clinical outcomes at lower administrative cost, they could reduce the growth of the PACE-addressable population over the hold period.

PACE traces its origins to the On Lok Senior Health Services program established in San Francisco in 1983, which demonstrated that comprehensive community-based care for frail elders could achieve outcomes comparable to nursing home placement at materially lower total cost. The model was made permanent under the Balanced Budget Act of 1997 as a distinct Medicare and Medicaid benefit category. The PACE Innovation Act of 2015 removed the prior urban requirement and authorized rural PACE demonstration programs, opening an estimated 40 million additional Americans to PACE eligibility by geography. Despite this expansion, only 175 PACE programs operated nationally as of 2025, serving approximately 75,000 participants, a fraction of the 12 million dual-eligible Americans who meet the nursing-home-eligibility clinical criteria.

CMS sets Medicare PMPM rates using a county-level benchmark derived from Medicare Advantage payment rates, adjusted upward to reflect PACE participants' higher average acuity through the CMS-HCC risk adjustment model. Each participant is assigned a risk score based on their diagnosis history; a participant with multiple chronic conditions such as diabetes, congestive heart failure, and COPD generates a significantly higher risk-adjusted PMPM than a lower-acuity enrollee. The 2024 risk adjustment methodology update increased per-member payments for high-acuity PACE enrollees by approximately 8%, as CMS recalibrated the HCC model to better reflect the clinical complexity of the dual-eligible population. State Medicaid agencies set their Medicaid PMPM rates separately, typically benchmarked against projected Medicaid costs if the same participants were served in institutional settings.

Medicare Advantage penetration, now at 52% nationally and projected to reach 60% by 2028, is the primary structural demand driver for PACE enrollment growth. MA plans are required under federal regulation to inform members about PACE when they become nursing-home eligible; as MA penetration increases, a larger share of the dual-eligible population receives proactive PACE outreach. This creates a structurally expanding enrollment funnel largely independent of individual operators' marketing spend. In Meridian’s California service areas, MA penetration stands at 58%, approximately 6 points above the national average, partially explaining the company’s above-average California census rates relative to Arizona peers.

CMS reimbursement rates for PACE programs have increased 4–5% annually since 2023, with the 2024 risk adjustment changes representing the most significant structural shift in a decade. The revised methodology expanded the PACE-eligible population and increased per-member payments for high-acuity enrollees by approximately 8%. These tailwinds underpin management’s revenue growth assumptions.

Congressional budget proposals in 2025 included modifications to the CMS-HCC risk adjustment methodology that would cap PMPM rate increases for PACE programs at 2% annually through 2028, compared to the 4–5% trajectory since 2023. These proposals did not advance in the current legislative session but reflect ongoing congressional scrutiny of dual-eligible managed care cost trajectories. A rate cap scenario would reduce Meridian’s projected Year 3 revenue by approximately $8M–$12M and compress EBITDA margins by 1.5–2 percentage points. This scenario is modeled in full in the Investigation Agenda.

State-level regulatory environments create material variation in new center economics. California’s licensure process averages 22 months from initial application to first participant enrollment, compared to 10–14 months in Arizona and 8–12 months in Nevada, where Meridian targets 2 new center applications in Year 2. New Mexico, Meridian’s third target geography, averages 16–18 months following the state’s 2022 PACE regulatory framework update. Each month of delay adds approximately $180K in carrying costs per center (facility lease, pre-opening staffing, regulatory fees) before the center generates any capitation revenue. For a 6-center buildout, a systematic 7-month delay relative to CIM assumptions adds approximately $7.6M in unbudgeted pre-revenue costs.

Meridian’s competitive moat rests on four structural factors: regional density, regulatory barriers, payer relationship depth, and participant switching costs. Regional density creates a self-reinforcing advantage; centers within 30 miles of each other can share specialty clinicians, reducing per-center staffing costs by 8–12%. Meridian has achieved this density configuration in 2 of its 3 California sub-markets, generating approximately $640K in annualized overhead savings relative to single-center economics.

The density advantage compounds beyond clinician-sharing. Two Meridian centers within 25 miles share a pharmacy director ($180K salary), a compliance officer ($140K), and a quality assurance coordinator ($95K), in addition to certain IT infrastructure costs. The combined shared overhead benefit approximates $320K per center pair annually. As Meridian adds centers in its target geographies, those that achieve density proximity to existing centers will reach EBITDA breakeven faster than the 18-month average for isolated centers, a compounding economic advantage unavailable to single-center and dispersed-network operators.

The CMS PACE program creates a regulatory moat among the most significant in the managed care sector. Launching a new PACE program requires a federal PACE Program Agreement, a state-specific three-way contract between CMS, the state Medicaid agency, and the PACE organization, state facility licensure, and a minimum of 30 enrolled participants before any reimbursement begins. The full regulatory timeline from initial application to first reimbursement dollar averages 20–28 months, with California at the long end. This means a new competitor cannot enter a Meridian service area and become economically viable for at least two years after application, a barrier that limits competition to well-capitalized platforms with the operational infrastructure to sustain pre-revenue carrying costs.

Meridian’s California Medicaid managed care contracts have 3-year terms with auto-renewal provisions and include pricing structures tied to participant acuity rather than flat PMPM rates, a more sophisticated arrangement than the flat-rate contracts typical of smaller PACE operators. These contracts required 18–24 months to negotiate and contain minimum enrollment guarantees that create financial incentives for the MCO to actively refer eligible members to Meridian. Replication by a new entrant requires both a track record of clinical performance to justify acuity-tiering and a multi-year negotiation timeline, creating a durable payer relationship moat.

Participant switching costs are high by design. PACE participants receive all medical, social, and supportive services through a single provider. Changing PACE providers requires re-enrollment, new physician relationships, and disruption to established care plans, resulting in voluntary disenrollment rates below 5% annually across the industry. PACE’s all-inclusive model creates a depth of clinical and social relationship with participants that no episodic or fee-for-service alternative can replicate.

The primary structural vulnerability is clinical workforce dependency. Meridian’s 12 centers are staffed by 14 medical directors; loss of any single director creates a 6–8 month operational disruption during replacement. The geriatric physician pipeline is structurally constrained: secondary research estimates fewer than 7,200 board-certified geriatricians practicing in the US as of 2025, against demand from academic medical centers, hospice organizations, SNFs, and PACE programs. PACE-specific clinical competencies, including capitated risk management, interdisciplinary team leadership, and regulatory documentation, further narrow the effective physician pool. Scaling from 12 to 18 centers requires recruiting 8–10 additional medical directors over 36 months in this constrained market, a challenge management has not addressed in the CIM with a specific recruitment pipeline or retention package strategy.

PACE has emerged as a preferred infrastructure-adjacent PE target since 2020, driven by the alignment of recurring capitated revenue, structural demand tailwinds, high participant switching costs, and meaningful regulatory barriers to entry. The asset class characteristics closely parallel those of outpatient dialysis networks and specialty pharmacy platforms: high revenue visibility, low customer churn, and demand driven by demographics rather than discretionary spending. Institutional PE interest accelerated following the PACE Innovation Act and the subsequent relaxation of program caps, which signaled federal policy commitment to PACE expansion as a cost containment mechanism for the dual-eligible population.

Three comparable PACE transactions since 2022 establish a valuation range of 12–16x EBITDA for high-quality operators. The InnovAge take-private in Q3 2024, led by Welsh Carson Anderson& Stowe, closed at approximately 14.5x trailing EBITDA with a $2.1B enterprise value, implying approximately $67M per center. The transaction included a 15% management rollover and a 24-month earnout tied to new center openings and census ramp milestones, reflecting buyer uncertainty about the pace of growth execution. Welsh Carson had previously backed InnovAge during its IPO phase, giving the firm deep familiarity with PACE unit economics and regulatory dynamics that shaped favorable deal terms.

Two smaller transactions provide additional reference points: a 6-center PACE network acquisition in Florida at 12.8x EBITDA (Q1 2023) and a 3-center Maryland operator acquisition at 11.2x EBITDA (Q4 2022). The lower multiples in these transactions reflect smaller scale, limited geographic diversification, and the absence of established payer relationship infrastructure. A platform of Meridian’s size and California density would be expected to command a multiple at the upper end of this range, in the 14–16x zone, contingent on resolution of the Arizona census and licensure timeline questions.

Independent PACE operators face a structural tension between growth ambitions and capital availability. Each new center requires approximately $3.2M in buildout capital and operates at negative EBITDA for 18 months before reaching breakeven. Funding 6 new centers over 36 months implies $38M–$43M in total capital requirements, including pre-breakeven operating losses, that organic cash flow at current margins cannot support without constraining existing operations. Wellington Peak Capital’s equity would provide expansion capital while simultaneously bringing the management infrastructure, including operational partners, clinical advisory networks, and regulatory relationships, to execute the buildout at the projected pace.

Probable exit paths at the end of a 5–7 year hold include secondary PE sale (the most common path, as demonstrated by InnovAge), strategic acquisition by a national health plan seeking to vertically integrate dual-eligible risk, or a public market exit via IPO. The health plan acquisition thesis is gaining traction among large Medicaid MCOs, including Centene, Molina, and Elevance, which are evaluating PACE platform acquisitions as a mechanism to lock in dual-eligible population attribution at lower total cost of care than traditional managed care arrangements. A strategic acquirer premium of 20–30% above the secondary PE multiple would imply a terminal value of 16–18x EBITDA at exit for a platform of Meridian’s size and quality.

Key structural closing considerations include CMS change-of-ownership (CHOW) approval, which adds 90–120 days to standard closing timelines. California imposes an additional layer: any change in controlling interest requires a full California Department of Health Care Services review of the PACE program agreement, historically adding 5–7 months to the California-specific closing process. For a buyer acquiring a California-weighted platform like Meridian (8 of 12 centers in California), this creates a materially longer time-to-close than a nationally diversified platform, requiring careful purchase agreement structuring to address the extended regulatory review period and associated break-up fee and MAC provisions.

Cross-referencing CIM claims against independently produced materials from the Get Smart research process reveals a mixed reliability profile: two core market assumptions are well corroborated, but three operationally critical assumptions contain material discrepancies that require direct management clarification before the IC memo is finalized. The following table presents the systematic assessment.

CIM Fact-Check: Key Claims vs. Independent Sources

The three discrepancies are concentrated in operational execution claims rather than market-level assertions. The licensure timeline discrepancy (9 months vs. 14–22 months) is the most financially consequential, as it directly drives the Year 3 center count and associated revenue and EBITDA projections. The census rate discrepancy is the most immediately verifiable: Meridian should be asked to provide trailing 12-month center-level census data as a standard data room deliverable, and the two Arizona centers should be discussed explicitly in management presentations. The Year 3 EBITDA margin assumption, at 19%, requires that new centers achieve breakeven substantially faster than the historical pattern, which may be achievable with PE operational support but has not been demonstrated in the current independent operating context.

The CIM is broadly competent on market-level claims, where independent data sources provide reasonable corroboration. The reliability concern is concentrated in forward-looking operational assumptions, particularly around the licensure timeline and new center ramp, which represent the primary value creation thesis. The team should treat the CIM’s Year 3 financial projections as an upside scenario and model a base case anchored to the 16-month licensure estimate from Category 3 research before presenting to the IC.

The following investigation threads are prioritized by their potential impact on the investment recommendation. Items marked with a contradiction flag indicate areas where available evidence conflicts.

Dr. Sarah Chen, Former Vice President of Operations at ElderBridge Health, one of the largest independent PACE operators in the Southeast, provided detailed perspective on PACE market dynamics and operational constraints during a 60-minute expert interview. Dr. Chen oversaw clinical operations across 14 PACE centers over six years at ElderBridge. The purpose of the interview was to validate the target company's growth assumptions and understand the operational realities of scaling PACE center networks. [00:00–05:30]

Dr. Chen confirmed that CMS capitated rates for PACE programs have increased 4-5% annually over the past three years, with the most meaningful shift being the 2024 risk adjustment methodology changes that expanded the addressable population by approximately 2.3 million lives. She noted that Medicare Advantage penetration, currently at 52% nationally, is the primary demand driver as MA plans increasingly contract with PACE organizations for their highest-acuity members. These figures broadly confirm the estimates presented in CIM Section 4.2, though Dr. Chen indicated that the geographic distribution of this growth is uneven, with Southern and Southwestern states seeing disproportionately higher demand. [05:30–15:30]

The interview highlighted a core tension between demand and supply capacity. ElderBridge was growing enrollment at roughly 12% year-over-year when Dr. Chen departed, but the binding constraint was never patient demand; it was care center capacity. Each new PACE center requires state-level licensure involving regulatory review, site inspections, and community needs assessments. Dr. Chen's experience across three states suggests 14-18 months as the realistic licensure timeline, with California routinely taking22 months, significantly longer than the 9-month estimate cited in the CIM. This discrepancy has material implications for the target's projected center count by Year 3. [15:30–25:00]

Dr. Chen disclosed that ElderBridge lost two PACE contracts in Q3 2024, information not present in the data room. She attributes this to Meridian Senior Care's aggressive market entry strategy, which undercuts incumbent pricing by 8-12% on capitated rates while absorbing short-term losses to build market share. This competitive pressure is most acute in overlapping geographies, specifically Texas and Florida, where both operators have active licensure applications for new centers. [25:00–35:00]

Beyond licensure, physician recruitment emerged as the primary operational bottleneck for PACE center expansion. The average time-to-fill for medical directors is 8 months, and the pool of geriatric-trained physicians willing to work in PACE settings is fundamentally limited. Dr. Chen noted that ElderBridge's most successful centers were those that invested in physician pipeline programs with local residency programs, a strategy that takes 2-3 years to yield results but produces higher retention and clinical quality. [35:00–42:00]

The interview surfaced material findings that affect the growth model's capacity assumptions. The licensure timeline discrepancy (14-18 months versus 9 months) directly impacts the target's projected center count by Year 3. Combined with competitive pressure from Meridian and the physician recruitment bottleneck, the organic growth trajectory may be 20-30% below management's base case. These findings warrant immediate follow-up with management and an updated sensitivity analysis in the TAM/SAM model. [42:00–47:23]